A growth factor treatment helps improve cardiac functioning after heart attack in pigs.

To advance the possibility of off-the-shelf cardiac cell therapies, scientists devise an engineered cardiac stem cell that avoids stimulating a detrimental immune attack.

A study in mice reveals that stem cell transplants, currently in clinical trials, may not actually require the cells.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

Mutating a gene called CMAH in mice so it’s nonfunctional, as in humans, upped the animals’ chances of developing heart disease, a study finds.

Maps of diving cells before and after heart attacks in mice offer additional evidence against the existence of cardiac stem cells.

Among 11 infants treated to date, most survived and their heart function improved.

The organ’s blood-pumping capacity improved with the infusion of cells, a study shows.

Cardiologists have found a way to cool the human heart in a localized way to help reduce muscle damage from heart attacks.